Agreements have been reached with pharmaceutical giants Merck, Roche's Greentech, Novartis, Bristol-Myers Squibb, Amgen, Gilead, GSK, Sanofil and Boehringer Ingelheim, according to the Trump administration.
Similar agreements have previously been reached with AstraZeneca and Pfizer, among others. A total of 14 of the 17 major drugmakers targeted by Trump have now agreed to the price cuts. The remaining three are expected to sign after the Christmas holidays, according to Commerce Secretary Howard Lutnick.
"American drug prices will fall rapidly, and will soon be among the lowest in the developed world," Trump said at a press conference at the White House.
